This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dong, J.-T. Articles by Frierson, H. F. Search for Related Content PubMed PubMed Citation Articles by Dong, J.-T. Articles by Frierson, H. F., Jr.

Deletion at 13q21 Is Associated with Aggressive Prostate Cancers¹

Departments of Pathology [J-T. D., C. C., H. F. F.] and Biochemistry and Molecular Genetics [J-T. D., B. G. S.], University of Virginia Health System, Charlottesville, Virginia 22908, and Johns Hopkins Oncology Center, Baltimore, Maryland 21231 [J. T. I.]

Previous cytogenetic and molecular genetic analyses suggest that the q21 band of chromosome 13 harbors a tumor suppressor gene(s) involved in prostatic carcinogenesis. The precise genetic location, however, has not been defined. In this study, we examined prostate cancer specimens and cell lines/xenograft for genetic deletions at 13q21, using the methods of tissue microdissection and duplex PCR. Deletions at 13q21 were detected in 13 of 147 (9%) prostate cancer samples. Deletion of the same region was also detected in the LNCaP cell line and the PC-82 xenograft of prostate cancer. The overlapping region of deletion in LNCaP and PC-82 spans 3.1 cM or 2.9 cR, which is equivalent to 1–3 Mb. The endothelin receptor B gene, a possible tumor suppressor gene at 13q21, was not located in the region of deletion. Among the 13 prostate neoplasms with deletion at 13q21, 5 were metastases, and 7 were poorly differentiated primary tumors. The only primary tumor that was not poorly differentiated but had deletion occurred in one of the youngest patients (49 years) at diagnosis. These results provide evidence that 13q21 may harbor an unidentified gene(s) whose inactivation occurs in some aggressive carcinomas of the prostate. In addition, this study provides a framework for the cloning and identification of the 13q21 gene(s).

This article has been cited by other articles:

				D. Ng, O. Toure, M.-H. Wei, D. C. Arthur, F. Abbasi, L. Fontaine, G. E. Marti, J. F. Fraumeni Jr, L. R. Goldin, N. Caporaso, et al. Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia Blood, February 1, 2007; 109(3): 916 - 925. [Abstract] [Full Text] [PDF]

				X.-Y. Dong, C. Chen, X. Sun, P. Guo, R. L. Vessella, R.-X. Wang, L. W.K. Chung, W. Zhou, and J.-T. Dong FOXO1A Is a Candidate for the 13q14 Tumor Suppressor Gene Inhibiting Androgen Receptor Signaling in Prostate Cancer. Cancer Res., July 15, 2006; 66(14): 6998 - 7006. [Abstract] [Full Text] [PDF]

				R. von Knobloch, L. Konrad, P. J. Barth, H. Brandt, S. Wille, A. Heidenreich, R. Moll, and R. Hofmann Genetic Pathways and New Progression Markers for Prostate Cancer Suggested by Microsatellite Allelotyping Clin. Cancer Res., February 1, 2004; 10(3): 1064 - 1073. [Abstract] [Full Text] [PDF]

				W. G. Nelson, A. M. De Marzo, and W. B. Isaacs Prostate Cancer N. Engl. J. Med., July 24, 2003; 349(4): 366 - 381. [Full Text] [PDF]

				C. Chen, E.-R. Hyytinen, X. Sun, H. J. Helin, P. A. Koivisto, H. F. Frierson Jr, R. L. Vessella, and J.-T. Dong Deletion, Mutation, and Loss of Expression of KLF6 in Human Prostate Cancer Am. J. Pathol., April 1, 2003; 162(4): 1349 - 1354. [Abstract] [Full Text] [PDF]